These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 37648673)
1. DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia. Sexauer AN; Alexe G; Gustafsson K; Zanetakos E; Milosevic J; Ayres M; Gandhi V; Pikman Y; Stegmaier K; Sykes DB Blood Adv; 2023 Nov; 7(21):6685-6701. PubMed ID: 37648673 [TBL] [Abstract][Full Text] [Related]
2. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer. Madak JT; Bankhead A; Cuthbertson CR; Showalter HD; Neamati N Pharmacol Ther; 2019 Mar; 195():111-131. PubMed ID: 30347213 [TBL] [Abstract][Full Text] [Related]
3. A Patent Review of Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors as Anticancer Agents and their Other Therapeutic Applications (1999-2022). Gehlot P; Vyas VK Recent Pat Anticancer Drug Discov; 2024; 19(3):280-297. PubMed ID: 37070439 [TBL] [Abstract][Full Text] [Related]
4. ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer. Mullen NJ; Thakur R; Shukla SK; Chaika NV; Kollala SS; Wang D; He C; Fujii Y; Sharma S; Mulder SE; Sykes DB; Singh PK Cancer Lett; 2023 Jan; 552():215981. PubMed ID: 36341997 [TBL] [Abstract][Full Text] [Related]
5. Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells. Mohamad Fairus AK; Choudhary B; Hosahalli S; Kavitha N; Shatrah O Biochimie; 2017 Apr; 135():154-163. PubMed ID: 28196676 [TBL] [Abstract][Full Text] [Related]
6. DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation. Mullen NJ; Shukla SK; Thakur R; Kollala SS; Wang D; Chaika N; Santana JF; Miklavcic WR; LaBreck DA; Mallareddy JR; Price DH; Natarajan A; Mehla K; Sykes DB; Hollingsworth MA; Singh PK Elife; 2024 Jul; 12():. PubMed ID: 38973593 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia. So J; Lewis AC; Smith LK; Stanley K; Franich R; Yoannidis D; Pijpers L; Dominguez P; Hogg SJ; Vervoort SJ; Brown FC; Johnstone RW; McDonald G; Ulanet DB; Murtie J; Gruber E; Kats LM EMBO Mol Med; 2022 Jul; 14(7):e15203. PubMed ID: 35514210 [TBL] [Abstract][Full Text] [Related]
8. Development of a biomarker to monitor target engagement after treatment with dihydroorotate dehydrogenase inhibitors. Pontikos MA; Leija C; Zhao Z; Wang X; Kilgore J; Tornesi B; Adenmatten N; Phillips MA; Williams NS Biochem Pharmacol; 2022 Oct; 204():115237. PubMed ID: 36055381 [TBL] [Abstract][Full Text] [Related]
9. Pivotal role of dihydroorotate dehydrogenase as a therapeutic target in adult T-cell leukemia. Ishikawa C; Mori N Eur J Haematol; 2024 Jul; 113(1):99-109. PubMed ID: 38558052 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells. Lafita-Navarro MC; Venkateswaran N; Kilgore JA; Kanji S; Han J; Barnes S; Williams NS; Buszczak M; Burma S; Conacci-Sorrell M PLoS Genet; 2020 Nov; 16(11):e1009117. PubMed ID: 33201894 [TBL] [Abstract][Full Text] [Related]
11. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors. Vyas VK; Ghate M Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807 [TBL] [Abstract][Full Text] [Related]
12. Identification of Dihydroorotate Dehydrogenase Inhibitors Using the Cell Painting Assay. Schölermann B; Bonowski J; Grigalunas M; Burhop A; Xie Y; Hoock JGF; Liu J; Dow M; Nelson A; Nowak C; Pahl A; Sievers S; Ziegler S Chembiochem; 2022 Nov; 23(22):e202200475. PubMed ID: 36134475 [TBL] [Abstract][Full Text] [Related]
13. Functional expression of human dihydroorotate dehydrogenase (DHODH) in pyr4 mutants of ustilago maydis allows target validation of DHODH inhibitors in vivo. Zameitat E; Freymark G; Dietz CD; Löffler M; Bölker M Appl Environ Microbiol; 2007 May; 73(10):3371-9. PubMed ID: 17369345 [TBL] [Abstract][Full Text] [Related]
17. Redistribution of defective mitochondria-mediated dihydroorotate dehydrogenase imparts 5-fluorouracil resistance in colorectal cancer. Dong S; Zhang M; Cheng Z; Zhang X; Liang W; Li S; Li L; Xu Q; Song S; Liu Z; Yang G; Zhao X; Tao Z; Liang S; Wang K; Zhang G; Hu S Redox Biol; 2024 Jul; 73():103207. PubMed ID: 38805974 [TBL] [Abstract][Full Text] [Related]
18. SAR studies toward discovery of emvododstat (PTC299), a potent dihydroorotate dehydrogenase (DHODH) inhibitor. Baiazitov RY; Qi H; Arasu T; Lennox W; Cao L; Weetall M; Furia B; Zhuo J; Choi S; Kim MJ; Sheedy J; Davis T; Moon YC Eur J Med Chem; 2022 Dec; 244():114826. PubMed ID: 36242990 [TBL] [Abstract][Full Text] [Related]
19. Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects. Klotz L; Eschborn M; Lindner M; Liebmann M; Herold M; Janoschka C; Torres Garrido B; Schulte-Mecklenbeck A; Gross CC; Breuer J; Hundehege P; Posevitz V; Pignolet B; Nebel G; Glander S; Freise N; Austermann J; Wirth T; Campbell GR; Schneider-Hohendorf T; Eveslage M; Brassat D; Schwab N; Loser K; Roth J; Busch KB; Stoll M; Mahad DJ; Meuth SG; Turner T; Bar-Or A; Wiendl H Sci Transl Med; 2019 May; 11(490):. PubMed ID: 31043571 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti-SARS-CoV-2 Activity. Gege C; Hahn F; Wangen C; Häge S; Herrmann A; Uhlig N; Eberlein V; Issmail L; Klopfleisch R; Grunwald T; Marschall M; Kohlhof H; Vitt D ChemMedChem; 2024 Oct; 19(19):e202400292. PubMed ID: 38887198 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]